Letters
General medicine
Volume 187 - Issue 10

International conferences on rare diseases: initiatives in commitment, patient care and connections

Authors:  Yvonne A Zurynski, Katie N Reeve and Elizabeth J Elliott

Med J Aust 2007; 187 (10): 597. || doi: 10.5694/j.1326-5377.2007.tb01433.x
Published online: 19 November 2007
Download PDF (458 KB)
Share: Share on Blue Sky Share on Facebook Share on LinkedIn Share by email

To the Editor: The recent conference report by Knight and Taruscio highlights the need for a coordinated effort to fill knowledge gaps and improve service provision for Australians with rare diseases.1 Although, by definition, individual rare diseases occur infrequently, there are about 6000 rare diseases affecting 6%–10% of the population.2,3 This equates to 1.2 million Australians, 30 million people in Europe and 25 million in the United States. By comparison, diabetes affects 1.4 million Australians.4

It is increasingly acknowledged that low prevalence does not equate to low impact. Rare diseases often have their onset in childhood, continue throughout life, are difficult to diagnose, are disabling, and have significant impact on patients, their families, the community and health services.2,5 However, rare diseases receive such scant attention that they have been dubbed “orphan” diseases. Lack of epidemiological and scientific data has hindered development of evidence-based practice, policy and services.

To tackle the problem of rare diseases, the European Union, the US, Canada and New Zealand have established policies and agencies to foster research, and develop resources for clinicians, community information services, and appropriate health facilities. The National Institutes of Health in the US established the Office of Rare Diseases because:

. . . rare disease research requires the collaboration of scientists from multiple disciplines and the capacity to share access to geographically distributed national research resources and patient populations . . . knowledge about rare diseases may offer leads for scientific advancement in other rare diseases and in more common diseases.6

There is no coordinated national effort or policy in Australia.

Currently, there are 14 national paediatric surveillance units, including the Australian Paediatric Surveillance Unit (APSU), to which paediatricians contribute epi-demiological, clinical and outcome data on rare conditions of childhood.7 These data inform development of health policy and improved diagnosis and clinical management, and result in the establishment of cohorts, thereby enabling further research.7 The APSU is developing information resources for clinicians and the community on rare infections, genetic disorders, mental health conditions and injuries in children. In Australia, the APSU is the only provider of prospective national data on up to 16 rare childhood diseases concurrently, but it receives no ongoing core funding.

Sound evidence is needed to underpin development of policy and services. Sound evidence requires sound research into the causes, management and effects of rare diseases. Australian clinicians, researchers and, most importantly, patients and their families deserve the benefits of a coordinated national plan to address the common burden of rare diseases.

Authors

  • Yvonne A Zurynski1
  • Katie N Reeve1
  • Elizabeth J Elliott1,2
  • 1. Australian Paediatric Surveillance Unit, The Children’s Hospital at Westmead, Sydney, NSW.
  • 2. Discipline of Paediatrics and Child Health, University of Sydney, Sydney, NSW.

Correspondence: apsu@chw.edu.au

References

View this article on Wiley Online Library

More like this

General medicine Perspective 17 November 2025 Open Access

The CURE Asthma roadmap

Gary P Anderson, Anthony Flynn, Phil G Bardin, John D Blakey, Shyamali C Dharmage, Paul Foster, Peter G Gibson, Adam Jaffe, Alan James, Christine R Jenkins, Sundram Sivamalai, Peter D Sly, Guy B Marks, Vanessa M McDonald, Judy Wetttenhall

View more